Is AmerisourceBergen stock a Buy, Sell or Hold?
AmerisourceBergen stock has received a consensus rating of buy. The average rating score is and is based on 18 buy ratings, 13 hold ratings, and 0 sell ratings.What was the 52-week low for AmerisourceBergen stock?
The low in the last 52 weeks of AmerisourceBergen stock was 135.14. According to the current price, AmerisourceBergen is 112.49% away from the 52-week low.What was the 52-week high for AmerisourceBergen stock?
The high in the last 52 weeks of AmerisourceBergen stock was 174.60. According to the current price, AmerisourceBergen is 87.07% away from the 52-week high.What are analysts forecasts for AmerisourceBergen stock?
The 31 analysts offering price forecasts for AmerisourceBergen have a median target of 166.48, with a high estimate of 201.00 and a low estimate of 130.00. The median estimate represents a 91.31 difference from the last price of 152.02.AmerisourceBergen Stock Snapshot
151.95
Bid
5,400.00
Bid Size
152.04
Ask
10,000.00
Ask Size
3/17/2023
Date
4:15 PM
Time
1.47 M
Volume
152.05
Prev. Close
152.55
Open
30.27 B
Market Cap
202.26 M
Number of Shares
150.51
Day Low
152.55
Day High
152.02
135.14
52 Week Low
174.60
52 Week High
152.02
1.96
Dividend
1.31
Dividend Yield
12.18
P/E Ratio
83.02
Free Float in %
11.63
EPS 2023
4.78
Book Value per Share
13.44
Cash Flow per Share
AmerisourceBergen News More News
AmerisourceBergen Historical Prices
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
AmerisourceBergen Analyst Data
Total Analysts: 31
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 130.00
Median: 166.48
Highest: 201.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
AmerisourceBergen Analyst Opinions
- All
- Buy
- Hold
- Sell
| 02/02/23 | Mizuho | Maintained Hold | $170 | ||
| 02/02/23 | Baird Patrick & Co | Maintained Buy | $201 | ||
| 01/31/23 | UBS | Maintained Buy | $190 | ||
| 01/31/23 | Evercore | Maintained Buy | $185 | ||
| 01/12/23 | Argus Research Company | Maintained Buy | $190 | ||
| 01/11/23 | Baird Patrick & Co | Maintained Buy | $199 | ||
| 11/22/22 | Credit Suisse | Maintained Buy | $182 | ||
| 10/18/22 | Cowen and Company, LLC | Maintained Buy | $169 | ||
| 10/11/22 | Bank of America Merrill Lynch | Upgraded to Buy | $169 | ||
| 08/22/22 | Morgan Stanley | Maintained Hold | $176 | ||
| 08/04/22 | Credit Suisse | Maintained Buy | $175 | ||
| 07/20/22 | Argus Research Company | Maintained Buy | $170 | ||
| 07/11/22 | Evercore | Downgraded to Hold | $150 | ||
| 06/13/22 | UBS | Maintained Buy | $174 | ||
| 06/09/22 | Cowen and Company, LLC | Maintained Buy | $170 | ||
| 06/07/22 | Deutsche Bank | Upgraded to Buy | $178 | ||
| 05/27/22 | Morgan Stanley | Maintained Hold | $175 | ||
| 05/26/22 | Barclays Capital | Upgraded to Buy | $182 | ||
| 05/25/22 | Deutsche Bank | Maintained Hold | $167 | ||
| 05/05/22 | Deutsche Bank | Maintained Hold | $168 | ||
| 05/05/22 | Mizuho | Maintained Hold | $162 | ||
| 04/12/22 | Morgan Stanley | Downgraded to Hold | $178 | ||
| 02/03/22 | Mizuho | Maintained Hold | $139 | ||
| 01/11/22 | Barclays Capital | Maintained Hold | $152 | ||
| 12/17/21 | Morgan Stanley | Maintained Buy | $142 | ||
| 11/12/21 | Deutsche Bank | Maintained Hold | $153 | ||
| 11/08/21 | Credit Suisse | Maintained Buy | $145 | ||
| 11/05/21 | Barclays Capital | Maintained Hold | $135 | ||
| 08/31/21 | Morgan Stanley | Maintained Buy | $141 | ||
| 08/05/21 | Credit Suisse | Maintained Buy | $144 | ||
| 05/06/21 | Barclays Capital | Maintained Hold | $130 |
AmerisourceBergen Estimates* in USD
| 2023 | 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|---|
| Revenue | 252,046 | 265,696 | 280,613 | 297,979 | 315,690 |
| Dividend | 1.96 | 2.02 | 2.09 | - | - |
| Dividend Yield (in %) | 1.31 % | 1.35 % | 1.40 % | - | - |
| EPS | 11.63 | 12.60 | 13.70 | 15.24 | 16.03 |
| P/E Ratio | 13.21 | 12.20 | 11.22 | 10.09 | 9.59 |
| EBIT | 3,185 | 3,438 | 3,638 | 3,899 | 4,226 |
| EBITDA | 3,724 | 3,920 | 4,146 | 4,726 | 5,112 |
| Net Profit | 2,368 | 2,531 | 2,678 | 3,016 | 3,293 |
| Net Profit Adjusted | 2,392 | 2,550 | 2,706 | 3,016 | 3,293 |
| Pre-Tax Profit | 2,976 | 3,186 | 3,366 | 3,782 | 4,128 |
| Net Profit (Adjusted) | 2,852 | 3,221 | 3,385 | - | - |
| EPS (Non-GAAP) ex. SOE | 11.63 | 12.60 | 13.70 | 15.24 | 16.03 |
| EPS (GAAP) | 10.60 | 11.88 | 13.10 | 13.80 | 16.11 |
| Gross Income | 8,676 | 9,148 | 9,643 | 10,104 | 10,658 |
| Cash Flow from Investing | -1,531 | -473 | -484 | - | - |
| Cash Flow from Operations | 2,587 | 3,182 | 3,377 | 3,550 | 4,135 |
| Cash Flow from Financing | -1,436 | -1,610 | -1,522 | -500 | 0 |
| Cash Flow per Share | 13.44 | 18.87 | 18.71 | - | - |
| Free Cash Flow | 2,124 | 2,678 | 2,866 | 2,885 | 3,403 |
| Free Cash Flow per Share | 7.31 | 12.62 | 14.02 | - | - |
| Book Value per Share | 4.78 | 12.19 | 20.22 | - | - |
| Net Debt | 3,072 | 2,016 | 1,223 | - | - |
| Research & Development Exp. | - | - | - | - | - |
| Capital Expenditure | 1,172 | 1,203 | 1,261 | 666 | 732 |
| Selling, General & Admin. Exp. | 5,090 | 5,298 | 5,528 | - | - |
| Shareholder’s Equity | 1,091 | 2,089 | 3,200 | 3,400 | 5,958 |
| Total Assets | 58,388 | 60,425 | 63,429 | 67,455 | 72,720 |
| Previous Quarter |
Current Quarter ending 03/31/23 |
Next Quarter ending 06/30/23 |
Current Year ending 09/30/23 |
Next Year ending 09/30/24 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | 14 | 14 | 15 | 14 |
| Average Estimate | - | 3.308 USD | 2.813 USD | 11.635 USD | 12.596 USD |
| Year Ago | - | 3.220 USD | 2.620 USD | 11.030 USD | 11.635 USD |
| Publish Date | - | 2/1/2023 | 5/3/2023 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | 10 | 10 | 13 | 12 |
| Average Estimate | - | 60,408 USD | 63,344 USD | 252,046 USD | 265,696 USD |
| Year Ago | - | 57,719 USD | 60,065 USD | 238,587 USD | 252,046 USD |
| Publish Date | - | 2/1/2023 | 5/3/2023 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
AmerisourceBergen Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| COLLIS STEVEN H | 03/13/2023 | 10,499.00 | 257,967.00 | 150.00 | Sell | No |
| COLLIS STEVEN H | 03/13/2023 | 10,499.00 | 268,466.00 | 77.53 | Buy | No |
| Battaglia Silvana | 03/08/2023 | 359.00 | 11,704.45 | 150.00 | Sell | No |
| Miller Redonda | 03/08/2023 | 1,334.00 | 1,562.00 | n/a | Buy | No |
| McGee Henry Wadsworth III | 03/08/2023 | 1,334.00 | 20,479.00 | n/a | Buy | No |
| DURCAN DERMOT MARK | 03/08/2023 | 1,667.00 | 18,730.00 | n/a | Buy | No |
| HYLE KATHLEEN W | 03/08/2023 | 1,334.00 | 21,970.00 | n/a | Buy | No |
| NALLY DENNIS M | 03/08/2023 | 1,334.00 | 8,730.00 | n/a | Buy | No |
| GOCHNAUER RICHARD W | 03/08/2023 | 1,334.00 | 26,326.00 | n/a | Buy | No |
| Battaglia Silvana | 03/08/2023 | 1,211.00 | 12,063.45 | n/a | Buy | No |
| Kim Lorence H. | 03/08/2023 | 1,334.00 | 1,892.00 | n/a | Buy | No |
| GREENBERG LON R | 03/08/2023 | 1,334.00 | 24,879.00 | n/a | Buy | No |
| McGee Henry Wadsworth III | 03/04/2023 | 2,012.00 | 15,014.00 | n/a | Buy | No |
| NALLY DENNIS M | 03/04/2023 | 2,012.00 | 4,605.00 | n/a | Buy | No |
| HYLE KATHLEEN W | 03/04/2023 | 2,012.00 | 17,845.00 | n/a | Buy | No |
| Clark Gina | 02/28/2023 | 1,838.00 | 26,733.00 | 156.22 | Sell | No |
| Clark Gina | 02/28/2023 | 86.00 | 28,571.00 | 156.19 | Sell | No |
| COLLIS STEVEN H | 02/13/2023 | 10,499.00 | 257,967.00 | 159.28 | Sell | No |
| COLLIS STEVEN H | 02/13/2023 | 10,499.00 | 268,466.00 | 77.53 | Buy | No |
| Krikorian Lazarus | 02/06/2023 | 5,711.00 | 18,732.00 | 155.82 | Sell | No |
| Campbell Elizabeth S | 02/02/2023 | 1,486.00 | 16,088.41 | 156.73 | Sell | No |
| Krikorian Lazarus | 02/02/2023 | 1,683.00 | 24,325.00 | 156.73 | Sell | No |
| Campbell Elizabeth S | 02/02/2023 | 4,668.00 | 17,574.41 | n/a | Buy | No |
| Krikorian Lazarus | 02/02/2023 | 5,835.00 | 26,008.00 | n/a | Buy | No |
| Miller Redonda | 01/31/2023 | 228.00 | 228.00 | n/a | Buy | No |
AmerisourceBergen Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2022 | AmerisourceBergen Corp. | 1.84 | 1.36 | USD |
| 2021 | AmerisourceBergen Corp. | 1.76 | 1.47 | USD |
| 2020 | AmerisourceBergen Corp. | 1.66 | 1.71 | USD |
| 2019 | AmerisourceBergen Corp. | 1.60 | 1.94 | USD |
| 2018 | AmerisourceBergen Corp. | 1.52 | 1.65 | USD |
| 2017 | AmerisourceBergen Corp. | 1.46 | 1.76 | USD |
| 2016 | AmerisourceBergen Corp. | 1.36 | 1.68 | USD |
| 2015 | AmerisourceBergen Corp. | 1.16 | 1.22 | USD |
| 2014 | AmerisourceBergen Corp. | 0.94 | 1.22 | USD |
| 2013 | AmerisourceBergen Corp. | 0.84 | 1.37 | USD |
| 2012 | AmerisourceBergen Corp. | 0.52 | 1.34 | USD |
| 2012 | AmerisourceBergen Corp. | 0.52 | 1.20 | USD |
| 2011 | AmerisourceBergen Corp. | 0.43 | 1.15 | USD |
| 2010 | AmerisourceBergen Corp. | 0.32 | 1.43 | USD |
| 2010 | AmerisourceBergen Corp. | 0.32 | 1.04 | USD |
| 2009 | AmerisourceBergen Corp. | 0.21 | 0.94 | USD |
| 2008 | AmerisourceBergen Corp. | 0.15 | 0.80 | USD |
| 2007 | AmerisourceBergen Corp. | 0.10 | 0.44 | USD |
| 2006 | AmerisourceBergen Corp. | 0.05 | 0.22 | USD |
| 2005 | AmerisourceBergen Corp. | 0.03 | 0.16 | USD |
| 2004 | AmerisourceBergen Corp. | 0.03 | 0.22 | USD |
| 2003 | AmerisourceBergen Corp. | 0.03 | 0.22 | USD |
| 2002 | AmerisourceBergen Corp. | 0.03 | 0.17 | USD |
| 2001 | AmerisourceBergen Corp. | - | - | USD |
| 2000 | AmerisourceBergen Corp. | - | - | USD |
| 1999 | AmerisourceBergen Corp. | - | - | USD |
*Yield of the Respective Date
AmerisourceBergen Corp. Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 2.813 USD | Q2 2023 Earnings Release | 05/03/2023 |
| Earnings Report | - | Q3 2023 Earnings Release | 08/03/2023 |
| Earnings Report | - | Q4 2023 Earnings Release | 11/02/2023 |
| Earnings Report | - | Q1 2024 Earnings Release | 02/01/2024 |
AmerisourceBergen Corp. Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | 2.710 USD | Q1 2023 Earnings Release | 02/01/2023 |
| Press Conference | - | - | 11/03/2022 |
| Press Conference | - | - | 08/03/2022 |
| Press Conference | - | - | 05/04/2022 |
AmerisourceBergen Profile
AmerisourceBergen Corp. engages in the provision of pharmaceutical products and business solutions that improve access to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical Distribution Services segment distributes an offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, and long-term care and alternate site pharmacies. The Other segment focuses on global commercialization services and animal health, and includes AmerisourceBergen Consulting Services ABCS, World Courier, and MWI. The company was founded by in Emil P. Martini in 1947 and is headquartered in Conshohocken, PA. .
Moody’s Daily Credit Risk Score
AmerisourceBergen Shareholder
| Owner | in % |
|---|---|
| Freefloat | 83.02 |
| Walgreens Boots Alliance, Inc. | 16.64 |
| Vanguard Group, Inc. (Subfiler) | 9.73 |
| State Street Corp. | 3.65 |
| JPMorgan Investment Management, Inc. | 2.80 |
| BlackRock Fund Advisors | 2.57 |
| Boston Partners Global Investors, Inc. | 2.57 |
| Vanguard Total Stock Market Index Fund | 2.50 |
| Fidelity Management & Research Co. LLC | 2.30 |
| T. Rowe Price Associates, Inc. (Investment Management) | 2.06 |
| BlackRock Institutional Trust Co. NA | 1.93 |
| Vanguard Mid Cap Index Fund | 1.90 |
| Vanguard 500 Index Fund | 1.86 |
| Geode Capital Management LLC | 1.61 |
| Bessemer Investment Management LLC | 1.31 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
AmerisourceBergen Management
| Name | Job |
|---|---|
| Steven H. Collis | Chairman, President & Chief Executive Officer |
| Lazarus Krikorian | Chief Accounting Officer & Senior Vice President |
| Jennifer E. Dubas | Chief Compliance Officer & Senior Vice President |
| James Francis Cleary | Chief Financial Officer & Executive VP |
| Silvana Battaglia | Chief Human Resources Officer & Executive VP |
| Elizabeth S. Campbell | Chief Legal Officer & Executive Vice President |
| Robert P. Mauch | Chief Operating Officer & Executive Vice President |
| Leslie E. Donato | Chief Strategy Officer & Executive Vice President |
| Gina K. Clark | EVP, Chief Communications & Administration Officer |
| Sun Park | Executive VP & CFO-Pharmaceutical Distribution |
| Dennis M. Nally | Independent Director |
| Lorence H. Kim | Independent Director |
| Redonda G. Miller | Independent Director |
| Lon R. Greenberg | Independent Director |
| Richard W. Gochnauer | Independent Director |
| D. Mark Durcan | Independent Director |
| Kathleen W. Hyle | Independent Director |
| Henry Wadsworth McGee | Independent Director |
| Ornella Barra | Non-Independent Director |
| Ann Anaya | SVP, Chief Diversity Equity & Inclusion Officer |
| Kourosh Q. Pirouz | Secretary, VP & Associate General Counsel |
| Bennett S. Murphy | Senior Vice President-Investor Relations |
| Rafael Augusto Kosa Teixeira | Senior Vice President-Transformation |
| Jack F. Quinn | Treasurer & Senior Vice President |